Magainin-2 dosing & administration
Amphipathic 23-amino-acid antimicrobial peptide from Xenopus laevis skin — the founding member of the magainin family discovered by Michael Zasloff at NIH in 1987, operating through the toroidal pore membrane disruption model with broad-spectrum activity against Gram-positive and Gram-negative bacteria, whose synthetic derivative Pexiganan (MSI-78) advanced to Phase III clinical trials for diabetic foot ulcers
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Topical: Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.
Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.
1% cream (pexiganan, a magainin-2 analog)
Frequency
Twice daily
Duration
Up to 28 days
Pexiganan (MSI-78), a synthetic magainin-2 analog, was tested as a 1% topical cream in Phase 3 diabetic foot-ulcer trials and matched oral ofloxacin for clinical improvement (~85-90%) [6]. Native magainin-2 itself has no approved human dosing; figures reflect its clinical-stage analog.
Timing
Best time to take
Apply Magainin-2 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
With food?
As a topical product, Magainin-2 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
If stacking
Magainin-2 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Magainin-2 is administered Topical application (primary clinical route)—no injection required
Best sites
Storage
Before reconstitution
Store Magainin-2 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Magainin-2 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (twice daily)
As prescribed by your healthcare provider injection
Site: Topical application (primary clinical route)—rotate sites if applicable
Maintain a consistent schedule for optimal results with Magainin-2. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Application site burning/stinging, Local erythema, Mild pruritus, Increased wound exudate
Less common: Contact sensitization
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Magainin-2
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Magainin-2 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- High concentrations of divalent cations (Ca²⁺, Mg²⁺) in wound care products — can reduce electrostatic binding of cationic magainin to bacterial membranes — Use with caution—discuss with your healthcare provider.
- Anionic wound dressings or polyanion-containing products (alginate, hyaluronic acid at high concentrations) — may sequester cationic magainin peptides — Use with caution—discuss with your healthcare provider.
- Topical corticosteroids at the same site — may impair the local immune activation that magainin promotes — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Ge Y, MacDonald D, Henry MM, et al. · 1999
Magainin-like pexiganan peptide shows broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria from diabetic foot ulcers without cross-resistance to other antibiotics.
Lipsky BA, Holroyd KJ, Zasloff M · 2008
Research (2008) demonstrates magainin 2's potent antimicrobial activity and broad-spectrum effectiveness against pathogenic microorganisms.
McMillan KAM, Coombs MRP · 2020
Study (1996) elucidates the molecular mechanism of action and biological pathways by which magainin 2 produces therapeutic effects.
Hossain F, Billah MM, Yamazaki M · 2022
Research (2006) demonstrates magainin 2's potent antimicrobial activity and broad-spectrum effectiveness against pathogenic microorganisms.
Sancho-Vaello E, Kücükyildiz H, Gil-Carton D, et al. · 2025
Study (2006) characterizes the biological activity and functional properties of magainin 2.
Lipsky BA, et al. (Clinical Infectious Diseases) · 2008
Phase 3 RCTs of 1% topical pexiganan (a magainin-2 analog) twice daily showed clinical improvement equivalent to oral ofloxacin (~85-90%) with no emergent pexiganan resistance.
Head to head
Magainin-2 compared
Want the full picture?
The complete Magainin-2 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.